Real IntelligenceReviewIndependent Clinical Evaluation
Back to Atlas

Autonomous screening

LumineticsCore

Digital Diagnostics

Autonomously diagnoses more-than-mild diabetic retinopathy from retinal images at the point of care.

Designed for

Healthcare provider

Care setting

Primary care

Specialty

Ophthalmology, Primary care

Public evidence assessedReviewed August 31, 2026

Our assessment

Bottom line

LumineticsCore has a landmark prospective pivotal evidence base for autonomous diabetic retinopathy testing in primary care. Its diagnostic foundation is strong, while current-version implementation, referral completion, access, equity, and long-term outcomes remain separate questions.

Based on public sources. RIR did not independently test this product. This is not an endorsement or recommendation.

What the evidence supports

Reviewed sources establish a cleared autonomous diabetic retinopathy diagnostic workflow without specialist over-read.

What remains uncertain

Local imageability, subgroup performance, referral completion, and longitudinal patient outcomes require implementation-level review.

How it was studied

The pivotal IDx-DR study, now represented by LumineticsCore, enrolled 900 people in primary care offices and compared autonomous results with a Wisconsin Fundus Photograph Reading Center reference that included stereoscopic photography and OCT.

Product facts

Intended use
Automatically detect more-than-mild diabetic retinopathy in eligible adults with diabetes using compatible retinal images.
Represented version
FDA-cleared system formerly known as IDx-DR; current configuration requires confirmation
Regulatory context
LumineticsCore, formerly IDx-DR, received FDA De Novo authorization for a defined autonomous diagnostic use.

Sources reviewed

3 public sources represented in this evidence profile.

LumineticsCore predecessor pivotal trialPrimary evidenceLumineticsCore product overviewOfficial productLumineticsCore US indications for useOfficial documentation
For clinical and investment reviewEvidence context and questions for deeper review

Evidence source base

Peer-reviewed pivotal evidence with company and inventor involvement, plus FDA authorization and product labeling.

Important limitation

Pivotal accuracy and imageability do not establish local referral completion, current-version performance, equitable access, or long-term prevention of vision loss.

Questions to ask

  1. 01How often are images insufficient for analysis?
  2. 02How are patients with prior retinopathy excluded?
  3. 03What happens after a positive result?
Return to AtlasHow RIR evaluates evidence